A Second-Generation eIF4A RNA Helicase Inhibitor Exploits Translational Reprogramming as a Vulnerability in Triple-Negative Breast Cancer

Researchers developed an orally bioavailable rocaglate-based molecule, MG-002, which hindered ribosome recruitment and scanning via unscheduled and non-productive RNA clamping by the eukaryotic translation initiation factor 4A RNA helicase.